Unicycive Therapeutics Inc (UNCY) - Total Liabilities
Based on the latest financial reports, Unicycive Therapeutics Inc (UNCY) has total liabilities worth $18.94 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Unicycive Therapeutics Inc equity growth rate to track the company's year-over-year net asset growth rate.
Unicycive Therapeutics Inc - Total Liabilities Trend (2018–2025)
This chart illustrates how Unicycive Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data.
Unicycive Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Unicycive Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Eastern Co
NASDAQ:EML
|
USA | $92.03 Million |
|
CVC Brasil Operadora e Agencia
SA:CVCB3
|
Brazil | R$3.74 Billion |
|
American Rare EARTHS Ltd
AU:ARR
|
Australia | AU$1.22 Million |
|
Compañía Minera Autlán S.A.B. de C.V
MX:AUTLANB
|
Mexico | MX$407.26 Million |
|
AB VILKUSKIU PIEN.EO 029
F:UDW
|
Germany | €100.04 Million |
|
Corbus Pharmaceuticals Holding
NASDAQ:CRBP
|
USA | $17.37 Million |
|
Parkit Enterprise Inc
V:PKT
|
Canada | CA$153.26 Million |
|
Soc Centrale Bois Scieries Manche SA
PA:CBSM
|
France | €234.68 Million |
Liability Composition Analysis (2018–2025)
This chart breaks down Unicycive Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of Unicycive Therapeutics Inc.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.59 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.63 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.39 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Unicycive Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Unicycive Therapeutics Inc (2018–2025)
The table below shows the annual total liabilities of Unicycive Therapeutics Inc from 2018 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $18.94 Million | -21.86% |
| 2024-12-31 | $24.24 Million | +34.65% |
| 2023-12-31 | $18.00 Million | +448.11% |
| 2022-12-31 | $3.28 Million | +45.31% |
| 2021-12-31 | $2.26 Million | -21.39% |
| 2020-12-31 | $2.88 Million | +218.38% |
| 2019-12-31 | $903.00K | -26.88% |
| 2018-12-31 | $1.24 Million | -- |
About Unicycive Therapeutics Inc
Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester deriv… Read more